Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
V-Bio Ventures is a life science venture capital fund founded in 2015 and headquartered in Belgium. The firm specializes in co-creating startups and investing in early- to mid-stage companies that demonstrate high growth potential within the life sciences sector. V-Bio Ventures aims to transform scientific innovations into products that positively impact people's lives, particularly in the fields of biotechnology, healthcare, and agricultural technology.
As of 2024, V-Bio Ventures manages approximately €185 million across two funds, with Fund I launched in 2015 at around €75 million and Fund II achieving a final close of €110 million. The firm has expanded its team from seven to nine investment professionals to support the deployment of Fund II. V-Bio Ventures maintains a strong relationship with the VIB (Flanders Institute for Biotechnology), which enhances its deal sourcing capabilities and provides access to cutting-edge research.
V-Bio Ventures has established itself as a key player in the European life sciences investment landscape, actively engaging with spin-outs from mature companies and various research institutes. The firm is committed to identifying and financing innovations that address unmet medical needs and have significant societal or environmental impact.
V-Bio Ventures invests primarily in private companies that possess differentiated technologies addressing unmet needs, particularly within the therapeutics sector, which encompasses drug discovery and drug development. The firm focuses on early- to mid-stage investments, spanning pre-seed to Series B funding rounds. V-Bio Ventures has a geographic focus on Europe, actively seeking innovative and transformational technologies that demonstrate high societal and/or environmental impact potential.
The investment strategy emphasizes co-creating startups, often in collaboration with the VIB and other research institutions. V-Bio Ventures looks for companies that can leverage cutting-edge research to develop solutions in biotech, pharma, and agricultural sectors. The firm is particularly interested in technologies that can lead to significant advancements in therapeutics, diagnostics, and sustainable agriculture.
V-Bio Ventures has built a diverse portfolio of companies across various sectors within life sciences. Notable portfolio companies include:
These companies exemplify V-Bio Ventures' commitment to investing in transformative innovations that address critical healthcare challenges.
Christina Takke - Managing Partner. Christina has extensive experience in venture capital and life sciences, having led numerous investments in the biotech sector.
Dennis Pedri - Analyst. Dennis specializes in market analysis and due diligence, contributing to the firm's investment decision-making process.
Katja Rosenkranz - Partner. Katja brings a wealth of knowledge in drug development and has been instrumental in sourcing deals for the firm.
Martin Solleveld - Finance Manager. Martin oversees the financial operations of V-Bio Ventures, ensuring efficient fund management.
Mathias Falcenberg - Venture Partner. Mathias has a strong background in biotech investments and supports portfolio companies with strategic guidance.
To pitch V-Bio Ventures, startups should use the contact form available on their website at V-Bio Ventures Contact Page. The pitch deck should include a clear overview of the technology, market opportunity, and team background. V-Bio Ventures prefers detailed applications that demonstrate a strong understanding of the competitive landscape and potential impact.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions through mutual connections can significantly improve the chances of a timely response.
In February 2021, V-Bio Ventures announced the first close of its second fund at €78 million, which later reached a final close of €110 million in 2024. This expansion reflects the firm's growing influence in the life sciences investment space.
Recently, V-Bio Ventures led a €23 million Series A round for Sibylla Biotech, focusing on a novel therapeutic approach for undruggable diseases. This investment highlights the firm's commitment to supporting innovative solutions in the biotech sector.
V-Bio Ventures has also been active in sharing insights through blog posts covering biomedical research trends and updates on portfolio companies, indicating a strong engagement with the life sciences community.
What are V-Bio Ventures' investment criteria?
V-Bio Ventures focuses on early- to mid-stage companies in the life sciences sector, particularly those with differentiated technologies that address unmet medical needs. The firm seeks innovations in therapeutics, diagnostics, and sustainable agriculture.
How can startups apply or pitch to V-Bio Ventures?
Startups interested in pitching to V-Bio Ventures can visit their contact page at V-Bio Ventures Contact Page. The firm encourages detailed proposals that highlight the technology's potential impact and market opportunity.
What makes V-Bio Ventures different from other VC firms?
V-Bio Ventures has a unique affiliation with the VIB, which provides access to cutting-edge research and a strong deal flow from spin-outs and entrepreneurial initiatives. This relationship enhances their ability to co-create companies based on scientific innovations.
What is the geographic scope of V-Bio Ventures?
The firm primarily invests in Europe, focusing on companies that can leverage the region's strong life sciences research capabilities.
What is the typical check size for investments?
V-Bio Ventures invests in early- to mid-stage rounds, leading and co-leading funding rounds. While specific check sizes vary, they have led rounds such as the €23 million Series A for Sibylla Biotech.
What kind of post-investment involvement does V-Bio Ventures have?
V-Bio Ventures actively engages with its portfolio companies, providing operational support, mentorship, and access to their extensive network within the life sciences sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.